Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

AstraZeneca pays $1.3bn for gout-buster drug

Lucy Tobin
Monday 23 April 2012 20:49 BST
Comments

The burst of M&A activity in the pharmaceuticals industry continued yesterday when AstraZeneca announced a $1.26bn (£783m) deal to buy the US company Ardea Biosciences, which is working on a new medicine to battle gout.

Astra, Britain's second-biggest drugmaker, is facing a patent cliff, as lucrative blockbusters including its antipsychotic Seroquel begin to face generic competition, while several medicines in its pipeline have failed at late-stage trials.

Shareholders will hope the deal to buy California's Ardea for $32 a share – 54 per cent above its closing share price on Friday – will bolster Astra's prospects. Ardea's Lesinurad is in late-stage development as a potential treatment for chronic gout, which is expected to affect almost 17 million people by 2019.

David Brennan, AstraZeneca's chief executive, said: "The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout programme. These compounds have real potential to benefit patients."

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in